The Patient - Patient-Centered Outcomes Research

, Volume 7, Issue 3, pp 283–300 | Cite as

The Patient Perspective of Diabetes Care: A Systematic Review of Stated Preference Research

Systematic Review



The importance of understanding the perspective of patients towards their own care is increasingly recognized, both in clinical practice and in pharmaceutical drug development. Stated preference methods to assess the preference of patients towards different aspects of diabetes treatment have now been applied for over a decade.


Our goal was to examine how stated preference methods are applied in diabetes care, and to evaluate the value of this information in developing the patient perspective in clinical and policy decisions.


A systematic review was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. The information sources were MEDLINE, EMBASE, Biosis, Current Contents, Web of Science, CINAHL, PsycINFO, and EconLit.


Three contingent valuation studies and 11 discrete choice experiments were retrieved. The majority of studies were conducted from 2009 onwards, but some date back to 1998. The reasons provided for applying the stated preference methods were to help differentiate between products, or to enable inclusion of the patient’s perspective in treatment decisions. The main aspects of treatment examined were related to glucose control, adverse events, and drug administration. The majority of patients preferred glucose control over avoiding minor hypoglycemic events. Patient willingness to pay was above $US100/month for glucose control, avoiding immediate health hazards such as nausea, and oral or inhaled drug administration. Preference towards drug administration was highly associated with previous experience with injectable diabetes medicine.


The ability of a drug to lower glucose levels plays a decisive role in the choice between alternative treatments. Future research should strive to develop questionnaire designs relevant for the decision context of the study. That is, if the aim is to foster shared decision making, in clinical practice or drug development, this should guide the study design. Furthermore, concise reporting of all study dimensions—from the qualitative prework to the analysis stage—is warranted.


  1. 1.
    Mitka M. Monitoring glycemic control in diabetes: new standardized reference measure a useful tool. JAMA. 2007;298(19):2252.PubMedCrossRefGoogle Scholar
  2. 2.
    Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic control. J Diabetes Complicat. 2004;18(1):60–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283–97.PubMedCrossRefGoogle Scholar
  4. 4.
    American Diabetes Association. Standards of medical care in diabetes: 2014. Diabetes Care 2014;37 Suppl 1:S14–80.Google Scholar
  5. 5.
    Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473–8.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Jordan JL, Ellis SJ, Chambers R. Defining shared decision making and concordance: are they one and the same? Postgrad Med J. 2002;78(921):383–4.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Snow R, Humphrey C, Sandall J. What happens when patients know more than their doctors? Experiences of health interactions after diabetes patient education: a qualitative patient-led study. BMJ Open. 2013;3(11):e003583.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Golin CE, DiMatteo MR, Gelberg L. The role of patient participation in the doctor visit. Implications for adherence to diabetes care. Diabetes Care. 1996;19(10):1153–64.PubMedCrossRefGoogle Scholar
  9. 9.
    Gabbay M, Shiels C, Bower P, Sibbald B, King M, Ward E. Patient-practitioner agreement: does it matter? Psychol Med. 2003;33(2):241–51.PubMedCrossRefGoogle Scholar
  10. 10.
    Cvengros JA, Christensen AJ, Hillis SL, Rosenthal GE. Patient and physician attitudes in the health care context: attitudinal symmetry predicts patient satisfaction and adherence. Ann Behav Med. 2007;33(3):262–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Muhlbacher AC, Juhnke C. Patient preferences versus physicians’ judgement: does it make a difference in healthcare decision making? Appl Health Econ Health Policy. 2013;11(3):163–80.PubMedCrossRefGoogle Scholar
  12. 12.
    Chin MH, Drum ML, Jin L, Shook ME, Huang ES, Meltzer DO. Variation in treatment preferences and care goals among older patients with diabetes and their physicians. Med Care. 2008;46(3):275–86.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Porzsolt F, Clouth J, Deutschmann M, Hippler HJ. Preferences of diabetes patients and physicians: a feasibility study to identify the key indicators for appraisal of health care values. Health Qual Life Outcomes. 2010;8:125.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Zulman DM, Kerr EA, Hofer TP, Heisler M, Zikmund-Fisher BJ. Patient-provider concordance in the prioritization of health conditions among hypertensive diabetes patients. J Gen Intern Med. 2010;25(5):408–14.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Casparie AF, van der Waal MA. Differences in preferences between diabetic patients and diabetologists regarding quality of care: a matter of continuity and efficiency of care? Diabet Med. 1995;12(9):828–32.PubMedCrossRefGoogle Scholar
  16. 16.
    van der Waal MA, Casparie AF, Lako CJ. Quality of care: a comparison of preferences between medical specialists and patients with chronic diseases. Soc Sci Med. 1996;42(5):643–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the research consumer. Lancet. 2000;355(9220):2037–40.PubMedCrossRefGoogle Scholar
  18. 18.
    Hanley B, Truesdale A, King A, Elbourne D, Chalmers I. Involving consumers in designing, conducting, and interpreting randomised controlled trials: questionnaire survey. BMJ. 2001;322(7285):519–23.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Basch E. Toward patient-centered drug development in oncology. N Engl J Med. 2013;369(5):397–400.PubMedCrossRefGoogle Scholar
  20. 20.
    Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, et al. Incorporating the patient’s perspective into drug development and communication: an ad hoc task force report of the patient-reported outcomes (PRO) harmonization group meeting at the food and drug administration, February 16, 2001. Value Health. 2003;6(5):522–31.PubMedCrossRefGoogle Scholar
  21. 21.
    Hareendran A, Gnanasakthy A, Winnette R, Revicki D. Capturing patients’ perspectives of treatment in clinical trials/drug development. Contemp Clin Trials. 2012;33(1):23–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Bateman IJ, Carson RT, Day B, Hanemann M, Hanley N, Hett T, et al. Economic valuation with stated preference techniques: a manual. Cheltenham: Edward Elgar Publishing Ltd; 2002.CrossRefGoogle Scholar
  23. 23.
    de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21(2):145–72.PubMedCrossRefGoogle Scholar
  24. 24.
    Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ. 2000;320(7248):1530–3.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Ryan M, Gerard K. Using discrete choice experiments to value health care programmes: current practice and future research reflections. Appl Health Econ Health Policy. 2003;2(1):55–64.PubMedGoogle Scholar
  26. 26.
    Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health. 2011;14(4):403–13.PubMedCrossRefGoogle Scholar
  27. 27.
    Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a users guide. Pharmacoeconomics. 2008;26(8):661–77.PubMedCrossRefGoogle Scholar
  28. 28.
    Louviere JJ, Woodworth G. Design and analysis of simulated consumer choice or allocation experiments: an approach based on aggregate data. J Market Res 1983;20:350–67.Google Scholar
  29. 29.
    Lin PJ, Cangelosi MJ, Lee DW, Neumann PJ. Willingness to pay for diagnostic technologies: a review of the contingent valuation literature. Value Health. 2013;16(5):797–805.PubMedCrossRefGoogle Scholar
  30. 30.
    Oremus M, Tarride JE. A systematic review of the use of contingent valuation in Alzheimer’s disease research. Dementia. 2008;7(4):461–80.CrossRefGoogle Scholar
  31. 31.
    Diener A, O’Brien B, Gafni A. Health care contingent valuation studies: a review and classification of the literature. Health Econ. 1998;7(4):313–26.PubMedCrossRefGoogle Scholar
  32. 32.
    Ahola AJ, Groop PH. Barriers to self-management of diabetes. Diabet Med. 2013;30(4):413–20.PubMedCrossRefGoogle Scholar
  33. 33.
    Patrick AR, Fischer MA, Choudhry NK, Shrank WH, Seeger JD, Liu J, et al. Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. J Gen Intern Med. 2014;29(2):320–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12.PubMedCrossRefGoogle Scholar
  35. 35.
    Guimaraes C, Marra CA, Gill S, Simpson S, Meneilly G, Queiroz RH, et al. A discrete choice experiment evaluation of patients’ preferences for different risk, benefit, and delivery attributes of insulin therapy for diabetes management. Patient Prefer Adherence. 2010;4:433–40.PubMedCentralPubMedGoogle Scholar
  36. 36.
    Guimaraes C, Marra CA, Colley L, Gill S, Simpson S, Meneilly G, et al. Socioeconomic differences in preferences and willingness-to-pay for insulin delivery systems in type 1 and type 2 diabetes. Diabetes Technol Ther. 2009;11(9):567–73.PubMedCrossRefGoogle Scholar
  37. 37.
    Guimaraes C, Marra CA, Colley L, Gill S, Simpson SH, Meneilly GS, et al. A valuation of patients’ willingness-to-pay for insulin delivery in diabetes. Int J Technol Assess Health Care. 2009;25(3):359–66.PubMedCrossRefGoogle Scholar
  38. 38.
    van Gils PF, Lambooij MS, Flanderijn MH, van den Berg M, de Wit GA, Schuit AJ, et al. Willingness to participate in a lifestyle intervention program of patients with type 2 diabetes mellitus: a conjoint analysis. Patient Prefer Adherence. 2011;5:537–46.PubMedCentralPubMedGoogle Scholar
  39. 39.
    van Gils PF, Lambooij MS, Struijs JN, Flanderijn MH, van den Berg M, van den Berg B. Factors influencing valuation of- and willingness to participate in-A lifestyle intervention: an exploratory conjoint analysis with diabetes type 2 patients. Value Health. 2010;13(7):A296.CrossRefGoogle Scholar
  40. 40.
    Schiotz M, Bogelund M, Almdal T, Willaing I. Discrete choice as a method for exploring education preferences in a Danish population of patients with type 2 diabetes. Patient Educ Couns. 2012;87(2):217–25.PubMedCrossRefGoogle Scholar
  41. 41.
    Chang K. Comorbidities, quality of life and patients’ willingness to pay for a cure for type 2 diabetes in Taiwan. Public Health. 2010;124(5):284–94.PubMedCrossRefGoogle Scholar
  42. 42.
    Yen SH. Characterising patients’ preferences for information in doctor-patient interactions. Malays J Econ Stud. 2006;43(1–2):1–18.Google Scholar
  43. 43.
    Jacobsson F, Johannesson M, Borgquist L. Is altruism paternalistic? Econ J. 2007;117(520):761–81.CrossRefGoogle Scholar
  44. 44.
    Chen TT, Chung KP, Huang HC, Man LN, Lai MS. Using discrete choice experiment to elicit doctors’ preferences for the report card design of diabetes care in Taiwan—a pilot study. J Eval Clin Pract. 2010;16(1):14–20.PubMedCrossRefGoogle Scholar
  45. 45.
    Taylor S, Hourihan F, Krass I, Armour C. Measuring consumer preference for models of diabetes care delivered by pharmacists. Pharm Pract. 2009;7(4):195–204.Google Scholar
  46. 46.
    Basoglu N, Daim TU, Topacan U. Determining patient preferences for remote monitoring. J Med Syst. 2012;36(3):1389–401.PubMedCrossRefGoogle Scholar
  47. 47.
    Hoerger TJ, Johnson FR, Manjunath R, Mansfield C, Clayton LJ, Zhang P. High-risk individuals’ stated preferences and willingness-to-pay for diabetes risk-reduction programs. Diabetes. 2005;54(Suppl. 1):A611.Google Scholar
  48. 48.
    Al-Haddad M, Ibrahim MMI, Sulaiman SAS, Shafie AA, Maarup N. Cost benefit analysis of the diabetes self management program at a university health centre in Malaysia. J Clin Diagn Res. 2010;4(3):2521–30.Google Scholar
  49. 49.
    Bamer JC. Patient willingness to pay for diabetes disease state management programs. J Manag Pharm Care. 2001;1(2):85–95.Google Scholar
  50. 50.
    Cairns JA, Van Der Pol MM. The estimation of marginal time preference in a UK-wide sample (TEMPUS) project. Health Technol Assess 2000;4(1):i-iv, 1–83.Google Scholar
  51. 51.
    Sadri H. Contingent valuation of inhaled insulin: a canadian perspective. J Med Econ. 2007;10(4):475–87.CrossRefGoogle Scholar
  52. 52.
    Hauber AB, Johnson FR, Sauriol L, Lescrauwaet B. Risking health to avoid injections: preferences of Canadians with type 2 diabetes. Diabetes Care. 2005;28(9):2243–5.PubMedCrossRefGoogle Scholar
  53. 53.
    Aristides M, Weston AR, FitzGerald P, Reun CL, Maniadakis N. Patient preference and willingness-to-pay for Humalog Mix25 relative to humulin 30/70: a multicountry application of a discrete choice experiment. Value Health. 2004;7(4):442–54.PubMedCrossRefGoogle Scholar
  54. 54.
    Bøgelund M, Vilsboll T, Faber J, Henriksen JE, Gjesing RP, Lammert M. Patient preferences for diabetes management among people with type 2 diabetes in Denmark—a discrete choice experiment. Curr Med Res Opin. 2011;27(11):2175–83.PubMedCrossRefGoogle Scholar
  55. 55.
    Jendle J, Torffvit O, Ridderstrale M, Lammert M, Ericsson A, Bogelund M. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes. Curr Med Res Opin. 2010;26(4):917–23.PubMedCrossRefGoogle Scholar
  56. 56.
    Hauber AB, Mohamed AF, Johnson FR, Falvey H. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26(4):416–24.PubMedCrossRefGoogle Scholar
  57. 57.
    Davey P, Grainger D, MacMillan J, Rajan N, Aristides M, Dobson M. Economic-evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness-to-pay approach. Pharmacoeconomics. 1998;13(3):347–58.PubMedCrossRefGoogle Scholar
  58. 58.
    Casciano R, Malangone E, Ramachandran A, Gagliardino JJ. A quantitative assessment of patient barriers to insulin. Int J Clin Pract. 2011;65(4):408–14.PubMedCrossRefGoogle Scholar
  59. 59.
    Gelhorn HL, Stringer SM, Brooks A, Thompson C, Monz BU, Boye KS, et al. Preferences for medication attributes among patients with type 2 diabetes mellitus in the United Kingdom. Diabetes Obes Metab. 2013;15(9):802–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Pinto SL, Holiday-Goodman M, Black CD, Lesch D. Identifying factors that affect patients’ willingness to pay for inhaled insulin. Res Social Adm Pharm. 2009;5(3):253–61.PubMedCrossRefGoogle Scholar
  61. 61.
    Sadri H, MacKeigan LD, Leiter LA, Einarson TR. Willingness to pay for inhaled insulin: a contingent valuation approach. Pharmacoeconomics. 2005;23(12):1215–27.PubMedCrossRefGoogle Scholar
  62. 62.
    Lloyd A, Nafees B, Barnett AH, Heller S, Ploug UJ, Lammert M, et al. Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus. Clin Ther. 2011;33(9):1258–67.PubMedCrossRefGoogle Scholar
  63. 63.
    Polster M, Zanutto E, McDonald S, Conner C, Hammer M. A comparison of preferences for two GLP-1 products—liraglutide and exenatide—for the treatment of type 2 diabetes. J Med Econ. 2010;13(4):655–61.PubMedCrossRefGoogle Scholar
  64. 64.
    Marshall D, Bridges JF, Hauber B, Cameron R, Donnalley L, Fyie K, et al. Conjoint analysis applications in health—how are studies being designed and reported?: an update on current practice in the published literature between 2005 and 2008. Patient. 2010;3(4):249–56.PubMedCrossRefGoogle Scholar
  65. 65.
    Alsahli M, Gerich JE. Hypoglycemia. Endocrinol Metab Clin North Am. 2013;42(4):657–76.PubMedCrossRefGoogle Scholar
  66. 66.
    Walker EA, Usher JA. Understanding and enhancing adherence in adults with diabetes. Curr Diab Rep. 2003;3(2):141–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Chatterjee JS. From compliance to concordance in diabetes. J Med Ethics. 2006;32(9):507–10.PubMedCentralPubMedCrossRefGoogle Scholar
  68. 68.
    Tests of Glycemia in Diabetes. Diabetes Care. 2003;26(suppl 1):s106–8.Google Scholar
  69. 69.
    Iqbal N, Morgan C, Maksoud H, Idris I. Improving patients’ knowledge on the relationship between HbA1c and mean plasma glucose improves glycaemic control among persons with poorly controlled diabetes. Ann Clin Biochem. 2008;45(5):504–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Hanas R, John G, On behalf of the International. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Diabetes Care. 2010;33(8):1903–4.PubMedCentralPubMedCrossRefGoogle Scholar
  71. 71.
    Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, et al. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011;10(7):495–506.PubMedCrossRefGoogle Scholar
  72. 72.
    Evans M, Khunti K, Mamdani M, Galbo-Jorgensen CB, Gundgaard J, Bogelund M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013;11:90.PubMedCentralPubMedCrossRefGoogle Scholar
  73. 73.
    Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22(8):1523–34.PubMedCrossRefGoogle Scholar
  74. 74.
    Polonsky WH, Davis CL, Jacobson AM, Anderson BJ. Correlates of hypoglycemic fear in type I and type II diabetes mellitus. Health Psychol. 1992;11(3):199–202.PubMedCrossRefGoogle Scholar
  75. 75.
    Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34(Supplement 2):S279–84.PubMedCentralPubMedCrossRefGoogle Scholar
  76. 76.
    Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf. 2007;30(12):1127–42.PubMedCrossRefGoogle Scholar
  77. 77.
    Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes–causes, effects and coping strategies. Diabetes Obes Metab. 2007;9(6):799–812.PubMedCrossRefGoogle Scholar
  78. 78.
    Larkin ME, Capasso VA, Chen CL, Mahoney EK, Hazard B, Cagliero E, et al. Measuring psychological insulin resistance: barriers to insulin use. Diabetes Educ. 2008;34(3):511–7.PubMedCrossRefGoogle Scholar
  79. 79.
    Fu AZ, Qiu Y, Radican L. Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes. Curr Med Res Opin. 2009;25(6):1413–20.PubMedCrossRefGoogle Scholar
  80. 80.
    Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care. 2005;28(11):2673–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Boxall PC, Adamowicz WL, Swait J, Williams M, Louviere J. A comparison of stated preference methods for environmental valuation. Ecol Econ. 1996;18(3):243–53.CrossRefGoogle Scholar
  82. 82.
    Gagnon MP, Desmartis M, Lepage-Savary D, Gagnon J, St-Pierre M, Rhainds M, et al. Introducing patients’ and the public’s perspectives to health technology assessment: a systematic review of international experiences. Int J Technol Assess Health Care. 2011;27(1):31–42.PubMedCrossRefGoogle Scholar
  83. 83.
    Hansen HP, Draborg E, Kristensen FB. Exploring qualitative research synthesis: the role of patients’ perspectives in health policy design and decision making. Patient. 2011;4(3):143–52.PubMedCrossRefGoogle Scholar
  84. 84.
    Facey K, Boivin A, Gracia J, Hansen HP, Lo SA, Mossman J, et al. Patients’ perspectives in health technology assessment: a route to robust evidence and fair deliberation. Int J Technol Assess Health Care. 2010;26(3):334–40.PubMedCrossRefGoogle Scholar
  85. 85.
    Bridges JF, Jones C. Patient-based health technology assessment: a vision of the future. Int J Technol Assess Health Care. 2007;23(1):30–5.PubMedCrossRefGoogle Scholar
  86. 86.
    Knottnerus JA, Tugwell P. The patients’ perspective is key, also in research. J Clin Epidemiol. 2012;65(6):581–3.PubMedCrossRefGoogle Scholar
  87. 87.
    Bridges JF. Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. Appl Health Econ Health Policy. 2003;2(4):213–24.PubMedGoogle Scholar
  88. 88.
    Ryan M, Scott DA, Reeves C, Bate A, van Teijlingen ER, Russell EM, et al. Eliciting public preferences for healthcare: a systematic review of techniques. Health Technol Assess. 2001;5(5):1–186.PubMedGoogle Scholar
  89. 89.
    Coast J, McDonald R, Baker R. Issues arising from the use of qualitative methods in health economics. J Health Serv Res Policy. 2004;9(3):171–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Center for Health Economic Research (COHERE)University of Southern DenmarkOdense MDenmark
  2. 2.Department of EpidemiologyNovo Nordisk A/SSøborgDenmark

Personalised recommendations